Urol. praxi, 2014; 15(4): 173-174

Fosfomycin in the treatment of urinary tract infections

MUDr.Jiří Slíva, Ph.D.
Ústavy farmakologie 2. a 3. LF UK, Praha

Uncomplicated urinary tract infections in adults are predominantly caused by E. coli, followed by staphylococci and other bacteria.

This article deals in brief the molecule of fosfomycin, which is currently recommended as drug of choice in this indication. Additionally,

pharmacodynamic properties, EAU recommendations, risk of resistance and compliance to proposed therapy are discussed.

Keywords: fosfomycin, urinary infections, antibiotics, compliance, resistance

Published: October 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Fosfomycin in the treatment of urinary tract infections. Urol. praxi. 2014;15(4):173-174.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Keating GM. Fosfomycin Trometamol: A Review of Its Use as a Single-Dose Oral Treatment for Patients with Acute Lower Urinary Tract Infections and Pregnant Women with Asymptomatic Bacteriuria. Drugs 2013. Go to original source...
    2. Parker S, Lipman J, Koulenti D, Dimopoulos G, Roberts JA. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int.J.Antimicrob.Agents 2013; 42: 289-293. Go to original source... Go to PubMed...
    3. Pasteran F, Lucero C, Rapoport M, et al. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae. J.Infect.Dev. Ctries. 2012; 6: 452-456. Go to original source... Go to PubMed...
    4. Grabe M, Bartoletti R, Bjerklund-Johansen TE, Cek HM. Guidelines on Urological Infections. http://www.uroweb.org/gls/pdf/19Urologicalinfections_LR.pdf. 2014. European Association of Urology Ref Type: Electronic Citation.
    5. Brumfitt W, Hamilton-Miller JM. Limitations of and indications for the use of co-trimoxazole. J Chemother. 1994; 6: 3-11. Go to original source... Go to PubMed...
    6. Rosales MJ, Vega F. Anaphylactic shock due to fosfomycin. Allergy 1998; 53: 905-907. Go to original source... Go to PubMed...
    7. Arca P, Reguera G, Hardisson C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J.Antimicrob.Chemother. 1997; 40: 393-399. Go to original source... Go to PubMed...
    8. Alos JI, Garcia-Pena P, Tamayo J. [Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections]. Rev.Esp.Quimioter. 2007; 20: 211-215. Go to PubMed...
    9. De BD, Korinek AM, Bismuth R, Trystram D, Coriat P, Puybasset L. Empirical treatment of adult postsurgical nosocomial meningitis. Acta Neurochir. (Wien.) 2002; 144: 989-995. Go to original source... Go to PubMed...
    10. Knothe H, Schafer V, Sammann A, Shah PM. Influence of fosfomycin on the intestinal and pharyngeal flora of man. Infection 1991; 19: 18-20. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.